Onconetix Acquires 100% Equity of Realbotix
Onconetix (ONCO) and Realbotix LLC (XBOTF) announced the signing of a definitive share exchange agreement pursuant to which Onconetix will acquire 100% of the issued and outstanding equity interests of Realbotix in an all-stock transaction. The company said, "Realbotix is Realbotix Corp's subsidiary that is focused on researching, designing, building and manufacturing AI-powered, highly customizable humanoid robotics. The robots are used for customer-facing roles in industries such as healthcare, education, hospitality and entertainment. Realbotix is a leader in embodied and physical AI with its patented technologies enabling lifelike expressions, vision, and social interaction. Its robots are known for their highly realistic human appearance and human-centric AI models. Realbotix robots are unique in their ability to operate autonomously via various AI platforms and do not require teleopertions from a human." Upon closing of the proposed transaction, Onconetix will acquire all the issued and outstanding equity interests of Realbotix in exchange for newly issued shares of common stock of Onconetix. Immediately following the closing of the transaction, Realbotix Parent will own between 75% and 90% of the fully diluted common shares of the combined company, depending upon Onconetoix's cash pooistion at closing. Mr. Kiguel will become the CEO of the combined company following closing. The transaction, which has been unanimously approved by the boards of directors of both Onconetix and Realbotix Parent, is subject to customary closing conditions, including approval by Onconetix shareholders, receipt of required regulatory approvals, including applicable securities law clearances in the United States and Canada, and other customary conditions. The transaction is expected to close in the second half of 2026, and the combined company is expected to trade on Nasdaq.
Trade with 70% Backtested Accuracy
Analyst Views on ONCO
About ONCO
About the author
What’s Behind the 50% Surge of This Micro-Cap Stock in Premarket Trading?
Merger Announcement: Onconetix is in the process of merging with Realbotix, a robotics company, which is expected to enhance its business focus on AI-powered humanoid robotics.
Stock Surge: Shares of Onconetix surged by 50% in pre-market trading following a 1-for-5 reverse stock split and news of the merger, indicating positive market sentiment.
Acquisition Details: The merger will give Realbotix's parent company a majority stake of up to 90% in the combined entity, with the deal expected to close in the second half of 2026.
Market Performance: Despite the surge, Onconetix shares have declined nearly 60% year-to-date, with retail sentiment remaining neutral as trading volumes increased significantly.
Onconetix Partners with Realbotix for 6G Trial
- 6G Trial Participation: Onconetix (ONCO) announced Realbotix's involvement in Ericsson's world-first 6G over-the-air trial at its U.S. headquarters in Plano, Texas, marking Realbotix as Ericsson's first enterprise robotics client.
- Real-Time Interaction Showcase: During the trial, the Realbotix robot transmitted video and interacted in real-time over Ericsson's test network, demonstrating how next-generation wireless networks can support AI robotics and real-time video streaming, highlighting the high-speed, low-latency connectivity essential for future AI-driven technologies.
- AI-Agnostic Architecture: The demonstration underscored Realbotix's AI-agnostic architecture, allowing its humanoid robots to integrate with multiple AI systems, cloud platforms, and network environments, designed to enable operation across diverse ecosystems without reliance on a single AI provider.
- Acquisition Agreement Progress: Onconetix previously announced a definitive agreement to acquire Realbotix LLC in an all-stock transaction, with the combined company expected to trade on Nasdaq in the second half of 2026, subject to shareholder and regulatory approvals, indicating a strategic move in the robotics sector.
Onconetix Announces 1-for-5 Reverse Stock Split
- Reverse Stock Split Announcement: Onconetix has announced a 1-for-5 reverse stock split effective March 25, 2026, aimed at reducing the number of outstanding shares to comply with Nasdaq's minimum bid price requirement of $1.00 per share.
- Outstanding Shares Reduction: The reverse split will decrease the company's outstanding shares from approximately 3.6 million to about 0.7 million, significantly lowering the share count in the market, which may help elevate the stock price to meet Nasdaq's listing standards.
- Market Reaction: Following the announcement, Onconetix's stock price fell by 16.12% in premarket trading to $0.52, indicating a negative market response that could undermine investor confidence in the company's future prospects.
- Listing Compliance Pressure: The implementation of the reverse stock split highlights the ongoing pressure the company faces to maintain its Nasdaq listing, suggesting a need for further strategic adjustments to improve its financial performance.
Realbotix Enters All-Stock Acquisition Agreement with Onconetix
- Acquisition Agreement: Realbotix announced an agreement with Onconetix, where the latter will acquire Realbotix's wholly-owned subsidiary RealLLC in an all-stock transaction expected to close by Q3 2026, marking a significant strategic expansion for the company.
- Equity Structure Change: Under the terms, Realbotix will receive between 75% and 90% of Onconetix's common stock, with the exact percentage determined by Onconetix's net cash at closing, a flexible arrangement that will impact future capital structure and shareholder equity.
- Board Control: Following the transaction, Realbotix will have the right to appoint four out of five directors to the Onconetix board, ensuring Realbotix's influence in the new entity and providing security for future strategic decisions.
- Executive Appointment: Realbotix's new CFO, Scott Meyers, has been granted 150,000 options to purchase common shares at C$0.32, a move aimed at attracting and retaining key talent to support the company's long-term growth strategy.
ANDREW KIGUEL TO ASSUME CEO ROLE OF MERGED COMPANY AFTER CLOSURE, SAYS ONCONETIX INC.
- New CEO Announcement: Andrew Kigue will become the CEO of Combined Company following its recent closing.
- Company Transition: The announcement marks a significant leadership change as the company moves forward after its merger.
REALBOTIX CORP - ONCONETIX ACQUIRES FULL OWNERSHIP OF REALBOTIX, LLC THROUGH STOCK TRANSACTION
Acquisition Announcement: RealBotix Corp has announced its intention to acquire 100% of RealBotix, LLC in an all-stock deal.
Strategic Move: This acquisition is part of a strategic effort to consolidate resources and enhance the company's market position in the robotics and AI sector.
What’s Behind the 50% Surge of This Micro-Cap Stock in Premarket Trading?
Merger Announcement: Onconetix is in the process of merging with Realbotix, a robotics company, which is expected to enhance its business focus on AI-powered humanoid robotics.
Stock Surge: Shares of Onconetix surged by 50% in pre-market trading following a 1-for-5 reverse stock split and news of the merger, indicating positive market sentiment.
Acquisition Details: The merger will give Realbotix's parent company a majority stake of up to 90% in the combined entity, with the deal expected to close in the second half of 2026.
Market Performance: Despite the surge, Onconetix shares have declined nearly 60% year-to-date, with retail sentiment remaining neutral as trading volumes increased significantly.
Onconetix Partners with Realbotix for 6G Trial
- 6G Trial Participation: Onconetix (ONCO) announced Realbotix's involvement in Ericsson's world-first 6G over-the-air trial at its U.S. headquarters in Plano, Texas, marking Realbotix as Ericsson's first enterprise robotics client.
- Real-Time Interaction Showcase: During the trial, the Realbotix robot transmitted video and interacted in real-time over Ericsson's test network, demonstrating how next-generation wireless networks can support AI robotics and real-time video streaming, highlighting the high-speed, low-latency connectivity essential for future AI-driven technologies.
- AI-Agnostic Architecture: The demonstration underscored Realbotix's AI-agnostic architecture, allowing its humanoid robots to integrate with multiple AI systems, cloud platforms, and network environments, designed to enable operation across diverse ecosystems without reliance on a single AI provider.
- Acquisition Agreement Progress: Onconetix previously announced a definitive agreement to acquire Realbotix LLC in an all-stock transaction, with the combined company expected to trade on Nasdaq in the second half of 2026, subject to shareholder and regulatory approvals, indicating a strategic move in the robotics sector.
Onconetix Announces 1-for-5 Reverse Stock Split
- Reverse Stock Split Announcement: Onconetix has announced a 1-for-5 reverse stock split effective March 25, 2026, aimed at reducing the number of outstanding shares to comply with Nasdaq's minimum bid price requirement of $1.00 per share.
- Outstanding Shares Reduction: The reverse split will decrease the company's outstanding shares from approximately 3.6 million to about 0.7 million, significantly lowering the share count in the market, which may help elevate the stock price to meet Nasdaq's listing standards.
- Market Reaction: Following the announcement, Onconetix's stock price fell by 16.12% in premarket trading to $0.52, indicating a negative market response that could undermine investor confidence in the company's future prospects.
- Listing Compliance Pressure: The implementation of the reverse stock split highlights the ongoing pressure the company faces to maintain its Nasdaq listing, suggesting a need for further strategic adjustments to improve its financial performance.
Realbotix Enters All-Stock Acquisition Agreement with Onconetix
- Acquisition Agreement: Realbotix announced an agreement with Onconetix, where the latter will acquire Realbotix's wholly-owned subsidiary RealLLC in an all-stock transaction expected to close by Q3 2026, marking a significant strategic expansion for the company.
- Equity Structure Change: Under the terms, Realbotix will receive between 75% and 90% of Onconetix's common stock, with the exact percentage determined by Onconetix's net cash at closing, a flexible arrangement that will impact future capital structure and shareholder equity.
- Board Control: Following the transaction, Realbotix will have the right to appoint four out of five directors to the Onconetix board, ensuring Realbotix's influence in the new entity and providing security for future strategic decisions.
- Executive Appointment: Realbotix's new CFO, Scott Meyers, has been granted 150,000 options to purchase common shares at C$0.32, a move aimed at attracting and retaining key talent to support the company's long-term growth strategy.
ANDREW KIGUEL TO ASSUME CEO ROLE OF MERGED COMPANY AFTER CLOSURE, SAYS ONCONETIX INC.
- New CEO Announcement: Andrew Kigue will become the CEO of Combined Company following its recent closing.
- Company Transition: The announcement marks a significant leadership change as the company moves forward after its merger.
REALBOTIX CORP - ONCONETIX ACQUIRES FULL OWNERSHIP OF REALBOTIX, LLC THROUGH STOCK TRANSACTION
Acquisition Announcement: RealBotix Corp has announced its intention to acquire 100% of RealBotix, LLC in an all-stock deal.
Strategic Move: This acquisition is part of a strategic effort to consolidate resources and enhance the company's market position in the robotics and AI sector.
